Study Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Want to learn more about this trial?
Request More InfoInterventions
Methylation CytometryDIAGNOSTIC_TEST
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | United States |